Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Recainam SCHEMBL123002 | 0.99 | LMNA (0.50) | LMNAGFERANPEPPOLBEPHX1 | |
| Recainam SCHEMBL8417555 | 0.97 | LMNA (0.49) | LMNAGFERANPEPPOLBEPHX1 | |
| SCHEMBL11429114 | 0.91 | LCK (0.51) | LMNAGFERPOLB | |
| Recainam SCHEMBL125120 | 0.87 | KMT2A (0.54) | LMNAGFERKMT2ACYP2C9CYP1A2 | |
| SCHEMBL29409425 | 0.84 | ALDH1A1 (0.46) | LMNAGFEREPHX1MAPTHTT | |
| SCHEMBL11428483 | 0.83 | LMNA (0.54) | LMNAGFERANPEPPOLBEPHX1 | |
| SCHEMBL11426270 | 0.81 | LMNA (0.52) | LMNAGFERPOLBEPHX1KMT2A | |
| SCHEMBL11054954 | 0.80 | LMNA (0.54) | LMNAGFERPOLBEPHX1KMT2A | |
| SCHEMBL29430936 | 0.80 | LMNA (0.54) | LMNAGFERANPEPPOLBEPHX1 | |
| SCHEMBL11219143 | 0.79 | LMNA (0.51) | LMNAGFERPOLBEPHX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-4348413-A | Anti-arrhythmic N-[3-alkylaminopropyl]-N'-phenylureas | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-09-07 | — | — | US | claimed |
| EP-0007184-B1 | UREA DERIVATIVES, PROCESSES FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-06-30 | — | — | EP | claimed |
| US-4224242-A | ANTI-ARRHYTHMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-09-23 | — | — | US | claimed |
| WO-1980000151-A1 | N-(3-ALKYLAMINOPROPYL)-N'-PHENYLUREAS | AMERICAN HOME PROD (US) | 1980-02-07 | — | — | WO | claimed |
| EP-0007184-A1 | Urea derivatives, processes for preparing them and compositions containing them | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-01-23 | — | — | EP | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| WO-1980000151-A1 | N-(3-ALKYLAMINOPROPYL)-N'-PHENYLUREAS | AMERICAN HOME PROD (US) | 1980-02-07 | — | — | WO | disclosed |
| EP-0007184-A1 | Urea derivatives, processes for preparing them and compositions containing them | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | LMNA 2584/4885GFER 3472/4885ANPEP 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.